Reengineering LLC - Comment

Document ID: FDA-2012-N-0780-0002
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: August 16 2012, at 12:00 AM Eastern Daylight Time
Date Posted: September 5 2012, at 12:00 AM Eastern Standard Time
Comment Start Date: August 14 2012, at 12:00 AM Eastern Standard Time
Comment Due Date: October 5 2012, at 11:59 PM Eastern Standard Time
Tracking Number: 810e00a0
View Document:  View as format xml

View Comment

I propose a very high level of semantics for the exchange of data. The approach is called "Executable English", and it attaches slightly formalized, open vocabulary English sentences to tables of data, so that we know (and the machine knows) what the tables are supposed to mean in the real world. One can also optionally write syllogism-like rules, again in open vocabulary English, that say how the data tables can be meaningfully combined. The rules document knowledge about the data, and can also be run as question-answering applications, with English explanations of the results. Since the executable knowledge is in English, Google indexes and retrieves it, acting as a kind of registry. Here is an example that you can view, run and edit in a browser: www.reengineeringllc.com/demo_agents/MedMine2.agent (Please scroll down past the rules to see some labeled tables.) A system that supports this is called Internet Business Logic -- a Wiki and SOA endpoint for executable open vocabulary English Q/A over SQL and RDF. It's online at www.reengineeringllc.com . Shared use is free, and there are no advertisements

Attachments:

Reengineering LLC - internet_business_logic_in_a_nutshell

Title:
Reengineering LLC - internet_business_logic_in_a_nutshell

View Attachment: View as format pdf

Related Comments

    View All
Total: 30
Reengineering LLC - Comment
Public Submission    Posted: 09/05/2012     ID: FDA-2012-N-0780-0002

Oct 05,2012 11:59 PM ET
Novo Nordisk Inc - Comment
Public Submission    Posted: 10/17/2012     ID: FDA-2012-N-0780-0004

Oct 05,2012 11:59 PM ET
BioClinica - Comment
Public Submission    Posted: 10/19/2012     ID: FDA-2012-N-0780-0006

Oct 05,2012 11:59 PM ET
Duke University School of Medicine - Comment
Public Submission    Posted: 10/19/2012     ID: FDA-2012-N-0780-0007

Oct 05,2012 11:59 PM ET
Astellas Pharma Global Development, Inc. - Comment
Public Submission    Posted: 10/19/2012     ID: FDA-2012-N-0780-0008

Oct 05,2012 11:59 PM ET